Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities. The company has invested $4 billion in the past 15 years to expand its US operations, which began in 1991, and now has an annual domestic capacity to produce 12 billion finished doses of generic medicines.

"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," Hafrun Fridriksdottir, president, Hikma Rx, said in a press release (1). "Hikma and our 2300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”

“Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines with more than 180 injectable products in our portfolio and a growing pipeline,” Bill Larkins, president, Hikma Injectables, added. “This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients.”

Investment in affordability and community

“As a pharmacist and chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It’s important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today,” US Rep. Buddy Carter, R-Ga., said in the release.

“Hikma continues to invest in American workers, and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans’ access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete,” US Rep. Mike Carey, R-Ohio, said in the release.

Sustainability efforts

In other company news, Hikma published its 2024 Sustainability Report, detailing the company’s approach to sustainability.

"Access to medicines remains at the heart of everything we do at Hikma," said Tim Brooks, the company’s vice-president of Sustainability, in a press release (2). "This sustainability report highlights our belief that providing high-quality medicines is not just our business—it's our responsibility to our people, customers, healthcare professionals, patients and the communities we serve around the world. This year, we have further reinforced access to medicine as the core of our sustainability strategy by leveraging our strong manufacturing presence and working with stakeholders across the healthcare ecosystem.

“This key objective is supported by our commitment to our people, our planet, and our suppliers. Additionally, we have introduced metrics for each of these areas to demonstrate our performance and ensure sustainability remains embedded throughout our corporate strategy,” Brooks added.

References

1. Hikma Pharmaceuticals. Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic Manufacturing and Development of Essential Generic Medicines. Press Release. June 28, 2025.
2. Hikma Pharmaceuticals. Hikma Publishes its 2024 Sustainability Report Reinforcing Commitment to Global Access to Medicines. Press Release. June 30, 2025.
3. Hikma. Acting Responsibly. Hikma Sustainability Report 2024. June 30, 2025.